Search Results
Results found for "Jaume Lillo"
- ⛵Sailing the GPCR Seas: Your Weekly Research Voyage! ⦿ Nov 11 - 17, 2024
angiotensin II-induced calcium signaling in striatal neurons Rafael Rivas-Santisteban , Ana Muñoz , Jaume Lillo , Iu Raïch , Ana Rodríguez-Pérez , Gemma Navarro , José Labandeira-García , Rafael Franco Endomembrane
- How System-Level GPCR Thinking Prevents Discovery Failures
Breakthroughs this week: Eli Lilly cuts Zepbound prices; GNAI1 missense mutation study; rapid Gαs endosomal translocation. 🔍 This Week in Premium: Sneak Peek Industry insights: Lilly cuts Zepbound prices; Lilly
- Allosteric Binding Demystified: Smarter GPCR Drug Discovery
Breakthroughs this week: Decoding ADGRE5 signaling; Eli Lilly’s obesity pill vs Novo’s Wegovy; Certa Metabolic GPCRs in the spotlight; receptor motion tracking tools; obesity treatment race between Eli Lilly
- Signals in Motion: Pain, Metabolism & Terry’s Corner
Eli Lilly’s next moves with Orforglipron and its amylin analog are highly anticipated.
- New Tools, Smart Signals, and The Kenakin Brief
industry side, Novo Nordisk, Septerna, and Deep Apple advance billion-dollar GPCR programs, while Eli Lilly
- How to Design GPCR Drugs That Work in Vivo: Strategy, Tools, and Insights
Breakthroughs this week: Lilly to build $5B manufacturing facility in Virginia; Novo Nordisk flags drug
- 📰 GPCR Weekly News
the Formation of a Cross-Functional Scientific and Drug Discovery Advisory Board Sosei Heptares and Lilly
- How a Failed Med School Dream Sparked a GPCR Biotech Revolution
In August 2025, Superluminal Medicines announced a collaboration with Eli Lilly and Company to advance
- The Hidden Driver of GPCR Drug Success: Why Target Residence Time Matters More Than You Think
Breakthroughs this week: Novo Nordisk cuts Ozempic® cost; Nxera launches obesity pipeline; Superluminal–Lilly
- 📰 GPCR Weekly News, June 24 to 30, 2024
First R&D Milestone Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio Lilly
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
Indeed, incretin-based drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound are advancing diabetes
- 📰 GPCR Weekly News, February 27 to March 5, 2023
Design Pharmaceuticals has a new website Confo Therapeutics Announces Global Licensing Agreement with Lilly
- GPCR Buzz of the Week | Sep 23 - 29, 2024
Develop Protein Therapeutics with Generative AI Nxera Pharma receives approval of insomnia drug in Japan Lilly
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
FFA4 receptor signaling controls lipolysis at lipid droplets; novel atypical GPCR-arrestin complexes; Lilly's
- 📰 GPCR Weekly News
Out-Licensing Deal of the Year from Locust Walk Omass Therapeutics 2022 Review Sosei hooks millions from Eli Lilly
